It Seems Neurocrine Biosciences Incorporated (NASDAQ:NBIX) Will Go Down. Just Reported More Shorted Shares

July 17, 2017 - By Richard Conner

 It Seems Neurocrine Biosciences Incorporated (NASDAQ:NBIX) Will Go Down. Just Reported More Shorted Shares

Investors sentiment decreased to 1.06 in 2016 Q4. Its down 0.03, from 1.09 in 2016Q3. It dropped, as 33 investors sold Neurocrine Biosciences, Inc. shares while 67 reduced holdings. 23 funds opened positions while 83 raised stakes. 82.52 million shares or 1.88% less from 84.11 million shares in 2016Q3 were reported.
Natl Bank Of Montreal Can stated it has 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). First Personal Fin Svcs stated it has 0% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Blackrock Institutional Tru Na has invested 0.01% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Jgp Gestao De Recursos Ltda owns 5,763 shares. Moreover, Columbus Circle Invsts has 0.08% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 155,827 shares. Capital World holds 0.01% or 1.19 million shares in its portfolio. Cubist Systematic Strategies Ltd reported 0.03% stake. Amalgamated State Bank accumulated 15,315 shares. Nationwide Fund reported 104,709 shares. First Republic Inv Mgmt invested 0.01% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Gam Ag reported 106,500 shares. Bank Of Ny Mellon Corp accumulated 0.02% or 1.40 million shares. The Ontario – Canada-based Royal Comml Bank Of Canada has invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). The New York-based D E Shaw & Communications Inc has invested 0.01% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Price T Rowe Assocs Inc Md holds 0.05% or 5.98M shares in its portfolio.

Since February 1, 2017, it had 0 insider purchases, and 24 insider sales for $11.36 million activity. On Monday, February 6 the insider Lloyd-Smith Malcolm sold $36,545. The insider RASTETTER WILLIAM H sold $454,510. $269,900 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares were sold by Nevinny Corinne H. 10,000 shares valued at $550,000 were sold by Grigoriadis Dimitri E. on Tuesday, May 2. On Monday, February 6 the insider BENEVICH ERIC sold $41,287. 1,375 shares were sold by Bozigian Haig P., worth $58,534 on Friday, February 3. GORMAN KEVIN CHARLES had sold 3,010 shares worth $129,972 on Monday, February 6.

The stock of Neurocrine Biosciences Incorporated (NASDAQ:NBIX) registered an increase of 15.97% in short interest. NBIX’s total short interest was 8.12M shares in July as published by FINRA. Its up 15.97% from 7.00 million shares, reported previously. With 1.13M shares average volume, it will take short sellers 7 days to cover their NBIX’s short positions. The short interest to Neurocrine Biosciences Incorporated’s float is 9.47%.

About 519,389 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 12.51% since July 17, 2016 and is uptrending. It has underperformed by 4.19% the S&P500.

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development platform, focused on neurological and endocrine based diseases and disorders. The company has market cap of $4.21 billion. The Company’s three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease. It currently has negative earnings. The Company’s product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 9 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci had 13 analyst reports since August 18, 2015 according to SRatingsIntel. Oppenheimer maintained it with “Buy” rating and $7000 target in Wednesday, July 5 report. The firm earned “Buy” rating on Tuesday, August 18 by Jefferies. The firm has “Outperform” rating by BMO Capital Markets given on Thursday, April 7. Oppenheimer initiated Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Tuesday, November 22 with “Perform” rating. The stock has “Buy” rating by Needham on Tuesday, October 18. The rating was maintained by Jefferies with “Buy” on Monday, June 26. As per Friday, January 27, the company rating was upgraded by Oppenheimer. The firm has “Outperform” rating given on Monday, October 12 by Leerink Swann. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Overweight” rating by Piper Jaffray on Thursday, October 8. On Tuesday, July 11 the stock rating was maintained by H.C. Wainwright with “Buy”.

More notable recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: which released: “Neurocrine Biosciences: Ingrezza Approved, Additional Catalysts Coming” on April 20, 2017, also with their article: “Neurocrine Poised To Corner Tardive Dyskinesia Market With Ingrezza” published on July 10, 2017, published: “Neurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global …” on June 04, 2017. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were released by: and their article: “Neurocrine Biosciences: Premium Ingrezza Pricing And Cash Influx Add To Bull Case” published on May 01, 2017 as well as‘s news article titled: “Neurocrine Stumbles With Ingrezza In Pediatric Tourette’s” with publication date: May 24, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.